Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS's new effort aims to do away with a complex model that typically determines how much pharmacies get reimbursed and how much patients pay for medications.

CVS to change how it prices prescription drugs with new pharmacy reimbursement model

Drugstore chain CVS guided fiscal 2024 revenue higher than expected, and raised the quarterly dividend by 10%.

CVS Stock Is Climing on Upbeat Revenue Guidance, Higher Dividend

CVS Health Corp (NYSE:CVS) confirmed guidance for adjusted earnings as it reported a solid jump in third-quarter sales.  The company said in the three months ended September 30 that total revenue increased 10.6% to $89.8 billion from the year before, with net income of $2.27 billion compared to a net loss $3.40 billion before.

CVS Health reports jump in sales despite challenging environment

CVS Health on Tuesday forecast 2024 revenue above Wall Street estimates and an in-line profit as the company expects to benefit from its expansion into health services and strength in its health insurance business.

CVS forecasts 2024 revenue above estimates on health services demand

CVS Health Inc.'s stock CVS, rose 3% premarket Tuesday, after the drug-store chain backed guidance for 2023 and set guidance for 2024 with revenue that's comfortably above consensus. The company said it expects 2024 adjusted EPS of at least 8.50 on revenue of at least $866.0 billion.

CVS Health's stock pops 3% after it offers above-consensus revenue guidance for 2024

Introduces CVS CostVantageTM and CVS Caremark TrueCostTM to drive aligned incentives and deliver a more transparent and sustainable reimbursement model Launches CVS HealthspireTM brand for Health Services segment that simplifies access to multi-payor capabilities, better aligns client service, and drives better outcomes and greater lifetime member value Demonstrates ability to unlock value across superior assets including CVS Caremark®, Aetna®, and CVS Pharmacy® businesses Announces quarterly dividend of sixty-six and a half cents ($0.665 cents) per share, an approximate 10% increase Reiterates 2023 financial guidance and initiates 2024 projections, outlining achievable long-term growth expectations with clear opportunities to outperform WOONSOCKET, R.I. , Dec. 5, 2023 /PRNewswire/ -- Today at its 2023 Investor Day, CVS Health® (NYSE: CVS) will share how its strategy and combination of assets drives reliable, diversified, and accelerating earnings growth, while also delivering superior care and value to millions of Americans.

CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer

CVS Health is rebranding its healthcare services operations under a new name, “CVS Healthspire.”

CVS To Rebrand Growing Health Services As ‘CVS Healthspire'

Agree Realty

Caesars Entertainment

Energy Transfer LP Unit

Mobileye Global Inc

Teck Resources

Yum China Hlds

In many, if not most cases, you want to avoid betting on the same horse, which makes the concept of hidden-gem stocks quite compelling. Generally, the equities sector features at least moderate efficiency, meaning that security has absorbed the collective weight of all publicly available information.

Silent Winners: 7 Low-Buzz Stocks With High Potential

CVS Health's (CVS) Health Care Benefits segment demonstrates value to consumers and clients by successfully managing drug cost trends and bringing innovative clinical solutions to the market.

CVS Health's (CVS) Digital Focus Aids Growth, Macro Issues Ail

Kenvue

Patterson Companies

Premier

Select Medical Holdings

Spok Holdings

U.S. Physical Therapy

With concerns about a slowdown in the global economy rising, investors may be better served considering the top healthcare hidden-gem stocks. To be sure, no guarantees exist in the market; otherwise, everyone would pour money into the guaranteed space.

Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio

Shares in CVS Group (AIM:CVSG) were little moved by its trading update, with analysts saying there was little new news, as the big news remains the ongoing Competition and Markets Authority review of the veterinary services sector. Revenue growth was up 11.9% in the four-month period to 31 October and EBITDA margins were in line with a year ago at roughly 19%.

CVS holds still on update, CMA update in early 2024 remains key say analysts

Investing is a complex game, but the aim is simple: Profit. Despite there being numerous avenues through which this objective can be achieved, many concentrate on short-term price movement and growth.

Is it time to buy this market-beaten growth stock?

CVS Health Corp is an appealing option for investors who play the long game. The company is undergoing a transition. Potential rewards are mixed in amidst the uncertainty. CVS has a sound balance sheet, generates strong cash flows, and has an attractive valuation.

CVS Health: Play The Long Game

Company previews: The vet probe that has cast a small shadow on Pets has loomed larger for more veterinary-focused CVS Group (AIM:CVSG), which may address investor concerns at its trading update

Halfords and CVS lead the line: Wednesday's preview

CVS Health has successfully built a well-diversified health-centric empire, offering retail, insurance, and healthcare services. The company's strategic acquisitions, such as Signify Health and Oak Street Health, provide opportunities for future growth and scale in the healthcare sector. CVS Health's digital innovation and strong financial position make it a strong competitor against online rivals like Amazon Pharmacy.

CVS Health: Not One Dividend Cut In 30 Years And A Good Upside

American Well Corporation

Doximity

Hims & Hers Health

Teladoc

The telehealth sector is undergoing a significant transformation, reshaping the traditional contours of medical service delivery. This innovation-driven domain is drawing attention from investors, as top telehealth stocks show potential in a rapidly expanding market.

5 Telehealth Stocks That Have Nothing But Upside

CVS Group (AIM:CVSG), the veterinary service provider, will hope the ongoing CMA probe into the industry doesn't overshadow its trading update on Wednesday. Britain's competition authority said in September it was investigating “how veterinary services are bought and sold amid concerns that pet owners may not be getting a good deal.

CVS to meet revenue targets despite looming vet probe, says experts

CVS is holding a highly anticipated investor day on December 5. Previous investor days were a positive catalyst for the stock, although investors are increasingly suspicious following the company's recent guidance cut. CVS's executive team has a lot on their plate, as they lead the company's way to become one of the largest healthcare services companies in the world.

CVS Health: All Eyes On December Investor Day

Target

Walmart

The manufacturer of eye drops sold under CVS Health Corp. CVS, -2.10%, Target Corp. TGT, -0.93%, Rite Aid Corp. RADCQ, +1.70%, Walmart Inc. WMT, -7.48% and other brands has recalled 27 products that were the subject of recent U.S. Food and Drug Administration warnings about potential contamination.

Eye-drop maker recalls CVS, Target, Walmart-branded products

Walgreens

The world of financial markets can be a brutal jungle, filled with dangers at every turn and businesses going bankrupt or turning billionaires almost overnight. Today, some of these risks and uncertain turning points have been assessed to bring you a sensible list of companies that can be termed as value stocks.

3 value stocks you shouldn't let go of this quarter

Johnson & Johnson

CVS Health's guidance cuts are weighing on the stock, but there are good reasons to buy now. Johnson & Johnson still faces legal issues, none of which look likely to derail its long-term goals.

2 Dividend Stocks Near Their 52-Week Lows to Buy and Hold Forever

AllianceBernstein Hld

Arbor Realty Trust

Ares Capital

Alexandria Real Estate Equities

AstraZeneca

BHP Billiton

British American Tobacco

Discover

Fifth Third Bancorp

Hasbro

Navient

NexPoint Residential Trust

Pfizer

Philip Morris

Vici Properties

March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five sets of stocks sorted as: “Inflation Busters.” Those five articles revealed 48 equities, with 43 paying dividends.

13 Buyable Inflation-Busting November Dividend Stocks

Apple

AbbVie

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

S&P 500 and Dow Jones dropped for the third straight month in October, just before staging a remarkable reversal in November. Interest rates were kept steady again in a range of 5.25% to 5.5%, and it is uncertain if 2023 will see yet another hike. Net investments of around $1,800 in October, primarily targeting the financial sector and high-yielding BDCs.

My Dividend Stock Portfolio: New October Dividend Record - 98 Holdings With 23 Buys

News for CVS Health Stock (CVS)